Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 2, 2006, Pages 654-657

  Athanassopoulos, George ^a   Pefanis, Angelos ^a   Sakka, Vissaria ^a   Iliopoulos, Dimitrios ^a   Perrea, Despina ^a   Giamarellou, Helen ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; LINEZOLID;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA VALVE DISEASE; ARTICLE; BACTERIAL ENDOCARDITIS; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; GRAM POSITIVE COCCI; HIGH RISK PATIENT; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RABBIT; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS ORALIS;

ACETAMIDES; ANIMALS; AORTIC VALVE; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECALIS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HEART VALVE DISEASES; OXAZOLIDINONES; RABBITS; STREPTOCOCCAL INFECTIONS;

EID: 31944440365     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.2.654-657.2006     Document Type: Article

References (26)

1. Bayer, A. S., and J. Tu. 1990. Chemoprophylactic efficacy against experimental endocarditis caused by β-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Antimicrob. Agents Chemother. 34:1068-1074.
2. Brauers, J., M. Kresken, D. Hafner, P. M. Shah, and the German Linezolid Resistance Study Group. 2005. Surveillance of linezolid resistance in Germany, 2001-2002. Clin. Microbiol. Infect. 11:39-46.
3. Buchanan, L. V., C. F. Dailey, R. J. LeMay, R. J. Zielinski, M. S. T. Kuo, and J. K. Gibson. 2002. Time-dependent antibacterial effects of linezolid in experimental rabbit endocarditis. J. Antimicrob. Chemother. 50:440-442.
4. Chiang, F. Y., and M. Climo. 2003. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:3002-3004.
5. Dailey, C. F., C. L. Dileto-Fang, L. V. Buchanan, M. P. Oramas-Shirey, D. H. Batts, C. W. Ford, and J. K. Gibson. 2001. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2304-2308.
6. Dailey, C. F., P. J. Pagano, L. V. Buchanan, J. A. Paquette, J. V. Haas, and J. K. Gibson. 2003. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 47:2655-2658.
7. Dajani, A. S., K. A. Taubert, W. Wilson, A. F. Bolger, A. Bayer, P. Ferrieri, H. Gewitz, S. T. Schulman, S. Nouri, J. W. Newburger, C. Hutto, T. J. Pallasch, T. W. Cage, M. E. Levison, G. Peter, and G. Zuccaro, Jr. 1997. Prevention of bacterial endocarditis: recommendations by the American Heart Association. Clin. Infect. Dis. 25:1448-1458.
8. Giacometti, A., R. Ghiselli, O. Cirioni, F. Mocchegiani, F. Orlando, M. S. Del Pretel, G. D'Amato, C. Silvestri, V. Saba, and G. Scalise. 2003. Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides. J. Antimicrob. Chemother. 52:724-726.
9. Glauser, M. P., and P. Francioli. 1987. Relevance of animal models to the prophylaxis of infective endocarditis. J. Antimicrob. Chemother. 20(Suppl. A):87-93.
10. Jacqueline, C., E. Batard, L. Perez, D. Boutoille, A. Hamel, J. Caillon, M. F. Kergueris, G. Pottel, and D. Bugnon. 2002. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob. Agents Chemother. 46:3706-3711.
11. Kennedy, H. F., C. G. Gemmell, J. Bagg, B. E. S. Gibson, and J. R. Michie. 2001. Antimicrobial susceptibility of blood culture isolates of viridans streptococci: relationship to a change in empirical antibiotic therapy in febrile neutropenia. J. Antimicrob. Chemother. 47:693-696.
12. McWhinney, P. H., S. Patel, R. A. Whiley, J. M. Hardie, S. H. Gillespie, and C. C. Kibbler. 1993. Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. Antimicrob. Agents Chemother. 37:2943-2945.
13. Moreillon, P., and the Swiss Working Group for Endocarditis Prophylaxis. 2000. Endocarditis prophylaxis revisited: experimental evidence of efficacy and new Swiss recommendations. Schweiz Med. Wochenschr. 130:1013-1026.
14. Mutnick, A. H., V. Enne, and R. N. Jones. 2003. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 37:769-774.
15. National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing, 14th informational supplement. M100-S15, vol. 24, no. 1. NCCLS, Wayne, PA.
16. Nishi, J., M. Yoshimaga, and Y. Nomura. 1999. Prevalence of penicillin-resistant viridans streptococci in the oral flora of Japanese children at risk for infective endocarditis. Circulation 99:1274-1275.
17. Oramas-Shirey, M. P., L. V. Buchanan, C. L. Dileto-Fang, C. F. Dailey, C. W. Ford, D. H. Batts, and J. K. Gibson. 2001. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J. Antimicrob. Chemother. 47:349-352.
18. Patel, R., M. S. Rouse, K. E. Piper, and J. M. Steckelberg. 2001. Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob. Agents Chemother. 45:621-623.
19. Peng, G. W., R. P. Stryd, S. Murata, M. Igarashi, K. Chiba, H. Aoyama, T. Zenki, and N. Ozawa. 1999. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J. Pharm. Biomed. Anal. 20:65-73.
20. Perdicaris, G., A. Pefanis, H. Giamarellou, A. Nikolopoulos, E. Margaris, I. Donta, A. Tsitsika, and P. Karayiannakos. 1997. Successful single-dose teicoplanin prophylaxis against experimental streptococcal enterococcal and staphylococcal aortic valve endocarditis. Antimicrob. Agents Chemother. 41:1916-1921.
21. Perlman, B. B., and L. R. Freedman. 1971. Experimental endocarditis. II: staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J. Biol. Med. 44:206-221.
22. Perry, C. M., and B. Jarvis. 2001. Linezolid. A review of its use in the management of serious gram-positive infections. Drugs 61:525-551.
23. Scheld, M. W., and M. A. Sande. 1995. Endocarditis and intravascular infections, p. 740-783. In G. L. Mandell, R. G. Douglas, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone. New York, N. Y.
24. Teng, L. J., P. R. Hsueh, Y. C. Chen, S. W. Ho, and K. T. Luh. 1998. Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis. J. Antimicrob. Chemother. 41:621-627.
25. Wise, R., J. M. Andrews, F. J. Boswell, and L. P. Ashby. 1998. The in-vitro activity of Linezolid (U-100766) and tentative breakpoints. J. Antimicrob. Chemother. 42:721-728.
26. Working Party of the British Society for Antimicrobial Chemotherapy. 1990. Antibiotic prophylaxis of infective endocarditis. Lancet 335:88-89.